Osiris Therapeutics, Inc. Common Stock
OSIR
OSIR was delisted on the 16th of April, 2019.
64 hedge funds and large institutions have $27.5M invested in Osiris Therapeutics, Inc. Common Stock in 2016 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 22 increasing their positions, 14 reducing their positions, and 8 closing their positions.
57% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 14
38% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 8
2% more funds holding
Funds holding: 63 → 64 (+1)
18% less capital invested
Capital invested by funds: $33.7M → $27.5M (-$6.21M)
72% less call options, than puts
Call options by funds: $327K | Put options by funds: $1.15M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$1.44M |
| 2 |
Millennium Management
New York
|
+$1.07M |
| 3 |
Morgan Stanley
New York
|
+$729K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$669K |
| 5 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$243K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$8.52M |
| 2 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
-$1.89M |
| 3 |
Goldman Sachs
New York
|
-$168K |
| 4 |
FIM
Freedom Investment Management
Hartford,
Connecticut
|
-$132K |
| 5 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$127K |
OSIR Hedge Fund Activity: Q4 2016 in Review
64 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Osiris Therapeutics, Inc. Common Stock (OSIR) for Q4 2016, worth a combined $27.5M — down 18% from $33.7M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new OSIR positions and 8 closed out — a net gain of 3 holders — while 22 added to existing stakes and 14 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $1.44M. The largest seller was Fidelity Investments, cutting an estimated $8.52M.
- 64 institutional investors held Osiris Therapeutics, Inc. Common Stock (OSIR) as of Q4 2016, up from 63 in Q3 2016.
- Funds reported $27.5M of Osiris Therapeutics, Inc. Common Stock stock for Q4 2016, down 18% quarter-over-quarter.
- 11 funds opened new Osiris Therapeutics, Inc. Common Stock positions in Q4 2016 and 8 closed out, a net change of +3 holders.
- The largest Osiris Therapeutics, Inc. Common Stock buyer in Q4 2016 was Renaissance Technologies, an estimated $1.44M added.
- The largest Osiris Therapeutics, Inc. Common Stock seller in Q4 2016 was Fidelity Investments, an estimated $8.52M sold.
Based on aggregated 13F filings for Q4 2016.